FDA inspection
Lykos Therapeutics, Inc.: FDA inspection ending May 15, 2024
FDA inspection 1239756 · Voluntary Action Indicated (VAI) · Santa Cruz, CA
Key facts
| Inspection ID | 1239756 |
|---|---|
| Firm | Lykos Therapeutics, Inc. |
| FEI number | 3025253687 |
| Address | 325 Soquel Ave |
| City | Santa Cruz |
| State | CA |
| ZIP | 95062 |
| Country | United States |
| Fiscal year | 2024 |
| Inspection end date | May 15, 2024 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Bioresearch Monitoring |
| Product type | Drugs |
At a glance
- 1–9 Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data